Published in Proc Natl Acad Sci U S A on December 27, 2005
TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A (2009) 3.70
Skin immune sentinels in health and disease. Nat Rev Immunol (2009) 3.52
Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med (2009) 2.66
The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet (2011) 2.48
Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med (2007) 2.20
Innate and adaptive interferons suppress IL-1α and IL-1β production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity (2011) 2.19
Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol (2008) 2.19
Immunology of psoriasis. Annu Rev Immunol (2014) 2.06
Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol (2008) 1.90
A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol (2010) 1.89
Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol (2010) 1.84
CD40 and autoimmunity: the dark side of a great activator. Semin Immunol (2009) 1.80
Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol (2008) 1.72
Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease. PLoS One (2012) 1.70
Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep (2007) 1.69
Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol (2012) 1.69
Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med (2008) 1.67
CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest (2009) 1.65
Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest (2006) 1.65
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol (2013) 1.59
iNOS-producing inflammatory dendritic cells constitute the major infected cell type during the chronic Leishmania major infection phase of C57BL/6 resistant mice. PLoS Pathog (2009) 1.53
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
CD8(+) T cells mediate RAS-induced psoriasis-like skin inflammation through IFN-γ. J Invest Dermatol (2012) 1.49
Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol (2015) 1.47
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. Cancer Cell (2016) 1.44
Keratinocyte but not endothelial cell-specific overexpression of Tie2 leads to the development of psoriasis. Am J Pathol (2009) 1.32
Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs (2010) 1.31
Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J Invest Dermatol (2008) 1.31
New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg (2010) 1.29
Type I interferons promote fatal immunopathology by regulating inflammatory monocytes and neutrophils during Candida infections. PLoS Pathog (2012) 1.26
Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allergy Clin Immunol (2010) 1.25
Cutaneous denervation of psoriasiform mouse skin improves acanthosis and inflammation in a sensory neuropeptide-dependent manner. J Invest Dermatol (2011) 1.23
Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy. Immunol Cell Biol (2010) 1.23
Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol (2013) 1.20
Combined use of laser capture microdissection and cDNA microarray analysis identifies locally expressed disease-related genes in focal regions of psoriasis vulgaris skin lesions. J Invest Dermatol (2012) 1.20
Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo. PLoS One (2010) 1.19
Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice. Br J Dermatol (2011) 1.17
Human dendritic cell functional specialization in steady-state and inflammation. Front Immunol (2014) 1.16
Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One (2011) 1.14
Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech (2012) 1.09
Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther (2014) 1.08
Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol (2009) 1.08
Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation. PLoS One (2013) 1.07
Plasticity of Ly-6C(hi) myeloid cells in T cell regulation. J Immunol (2011) 1.07
Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci (2010) 1.06
Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs (2014) 1.00
A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin. J Invest Dermatol (2012) 1.00
Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation. J Invest Dermatol (2009) 0.97
Deepening our understanding of immune sentinels in the skin. J Clin Invest (2007) 0.96
IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine (2013) 0.95
The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun (2015) 0.95
Human and Mouse Mononuclear Phagocyte Networks: A Tale of Two Species? Front Immunol (2015) 0.95
Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf (2012) 0.94
The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis. Int J Rheumatol (2012) 0.92
Coordinating innate immune cells to optimize microbial killing. Immunity (2008) 0.91
Specific roles for dendritic cell subsets during initiation and progression of psoriasis. EMBO Mol Med (2014) 0.89
Dendritic cells a double-edge sword in autoimmune responses. Front Immunol (2012) 0.87
Nitric oxide controls an inflammatory-like Ly6C(hi)PDCA1+ DC subset that regulates Th1 immune responses. J Leukoc Biol (2010) 0.87
Redox imbalance in T cell-mediated skin diseases. Mediators Inflamm (2010) 0.87
Genetic dysbiosis: the role of microbial insults in chronic inflammatory diseases. J Oral Microbiol (2014) 0.86
Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis. J Immunol (2013) 0.86
Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis. PLoS One (2012) 0.86
Human skin dendritic cells in health and disease. J Dermatol Sci (2014) 0.86
Harnessing dendritic cells in inflammatory skin diseases. Semin Immunol (2011) 0.86
The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res (2007) 0.84
What is a role of haeme oxygenase-1 in psoriasis? Current concepts of pathogenesis. Int J Exp Pathol (2007) 0.84
CD8 T cells regulate allergic contact dermatitis by modulating CCR2-dependent TNF/iNOS-expressing Ly6C+ CD11b+ monocytic cells. J Invest Dermatol (2013) 0.84
TREM-1 as a potential therapeutic target in psoriasis. J Invest Dermatol (2013) 0.83
Characteristics of "Tip-DCs and MDSCs" and Their Potential Role in Leishmaniasis. Front Microbiol (2012) 0.83
Identification of genes responsive to solar simulated UV radiation in human monocyte-derived dendritic cells. PLoS One (2009) 0.83
Dendritic cells in the pathogenesis of sarcoidosis. Am J Respir Cell Mol Biol (2009) 0.81
Tissue-resident dendritic cells and diseases involving dendritic cell malfunction. Int Immunopharmacol (2016) 0.80
Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients. Arthritis Res Ther (2012) 0.80
Innate-adaptive crosstalk: how dendritic cells shape immune responses in the CNS. Adv Exp Med Biol (2012) 0.80
No impairment of monocyte-derived Langerhans cell phenotype or function in early-onset psoriasis. Clin Exp Dermatol (2011) 0.80
Regulation of Dendritic Cell Function in Inflammation. J Immunol Res (2015) 0.79
Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs. PLoS One (2012) 0.79
The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases. J Allergy Clin Immunol (2015) 0.79
Rise in dermal CD11c+ dendritic cells associates with early-stage development of psoriatic lesions. Arch Dermatol Res (2012) 0.79
Immunobiologics in the treatment of psoriasis. Clin Immunol (2007) 0.79
Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol (2015) 0.78
Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci (2007) 0.78
The pathophysiological role of dendritic cell subsets in psoriasis. BMB Rep (2014) 0.78
Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics (2008) 0.77
Cutaneous microdialysis: cytokine evidence for altered innate reactivity in the skin of psoriasis patients? AAPS J (2012) 0.77
Dendritic cells as danger-recognizing biosensors. Sensors (Basel) (2009) 0.75
Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. BMC Dermatol (2007) 0.75
Dendritic Cells in Systemic Lupus Erythematosus: From Pathogenic Players to Therapeutic Tools. Mediators Inflamm (2016) 0.75
Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases. Clin Dev Immunol (2011) 0.75
Immunotargeting in the management of psoriasis. Immunotargets Ther (2013) 0.75
Current and potential immune therapies and vaccines in the management of psoriasis. Hum Vaccin Immunother (2014) 0.75
Monocyte-derived inflammatory Langerhans cells and dermal dendritic cells mediate psoriasis-like inflammation. Nat Commun (2016) 0.75
The role of nitric oxide in metabolic regulation of Dendritic cell immune function. Cancer Lett (2017) 0.75
Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol (2017) 0.75
A type of human skin dendritic cell marked by CD5 is associated with the development of inflammatory skin disease. JCI Insight (2017) 0.75
Dendritic Cells and Their Role in Allergy: Uptake, Proteolytic Processing and Presentation of Allergens. Int J Mol Sci (2017) 0.75
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 22.89
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med (2003) 14.60
Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell (2001) 13.24
Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci U S A (2000) 7.39
TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity (2003) 7.33
Dendritic cells: features and functions. Immunol Rev (1980) 6.34
Etanercept as monotherapy in patients with psoriasis. N Engl J Med (2003) 4.57
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med (2004) 4.02
Characterization of human blood dendritic cell subsets. Blood (2002) 3.97
Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med (2003) 3.89
A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci (2002) 2.62
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest (2004) 2.34
Sequential MyD88-independent and -dependent activation of innate immune responses to intracellular bacterial infection. Immunity (2003) 2.20
The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol (2002) 2.15
Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A (2005) 2.12
Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol (2004) 1.92
Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol (2002) 1.76
Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest (1994) 1.71
Combining several ordinal measures in clinical studies. Stat Med (2004) 1.71
A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine (2002) 1.65
Both dendritic cells and memory T lymphocytes emigrate from organ cultures of human skin and form distinctive dendritic-T-cell conjugates. J Invest Dermatol (1995) 1.40
Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol (1996) 1.31
Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol (2004) 1.27
Detection of nitric oxide and nitric oxide synthases in psoriasis. Arch Dermatol Res (1998) 1.25
CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun (2000) 1.13
Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol (2003) 1.05
PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med (1994) 1.02
The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol (2001) 1.01
Dendritic cells and immunity to Listeria: TipDCs are a new recruit. Trends Immunol (2004) 0.95
In situ expression of the costimulatory molecules CD80 and CD86 on langerhans cells and inflammatory dendritic epidermal cells (IDEC) in atopic dermatitis. Arch Dermatol Res (2001) 0.88
Adhesion of dendritic cells derived from CD34+ progenitors to resting human dermal microvascular endothelial cells is down-regulated upon maturation and partially depends on CD11a-CD18, CD11b-CD18 and CD36. Eur J Immunol (2002) 0.87
Differential antigen processing by dendritic cell subsets in vivo. Science (2007) 8.42
Pathogenesis and therapy of psoriasis. Nature (2007) 6.94
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med (2012) 6.17
A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity (2008) 5.89
Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell (2010) 5.28
In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med (2004) 5.07
Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood (2006) 5.05
The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med (2002) 4.78
DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med (2003) 4.69
Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med (2003) 4.41
CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med (2004) 4.35
Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med (2002) 4.32
Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med (2009) 4.27
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (2006) 4.26
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol (2008) 4.18
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med (2004) 4.02
Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol (2005) 3.75
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med (2007) 3.68
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med (2003) 3.67
Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol (2002) 3.61
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med (2004) 3.59
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet (2003) 3.52
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics (2003) 3.39
Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med (2014) 3.36
Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med (2002) 3.35
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA (2011) 3.29
A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med (2010) 3.11
The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol (2003) 3.06
Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med (2005) 2.90
Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med (2007) 2.86
Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol (2005) 2.83
A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med (2007) 2.82
IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol (2009) 2.77
Recent immune status determines the source of antigens that drive homeostatic T cell expansion. J Immunol (2005) 2.73
CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J Immunol (2008) 2.69
The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol (2004) 2.64
The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A (2008) 2.57
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum (2008) 2.56
Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med (2006) 2.53
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA (2003) 2.50
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum (2009) 2.49
Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol (2010) 2.46
Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J Clin Invest (2007) 2.46
Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med (2006) 2.43
HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation. Proc Natl Acad Sci U S A (2004) 2.38
A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q. Cell (2006) 2.37
Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood (2006) 2.36
TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol (2005) 2.29
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol (2007) 2.26
Macrophages control the retention and trafficking of B lymphocytes in the splenic marginal zone. J Exp Med (2003) 2.23
Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A (2005) 2.22
Influenza virus-induced dendritic cell maturation is associated with the induction of strong T cell immunity to a coadministered, normally nonimmunogenic protein. J Exp Med (2003) 2.20
Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol (2008) 2.19
Flt3 signaling-dependent dendritic cells protect against atherosclerosis. Immunity (2011) 2.14
Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A (2005) 2.12
Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med (2005) 2.10
Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A (2007) 2.10
Evaluation metrics for biostatistical and epidemiological collaborations. Stat Med (2011) 2.09
Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med (2011) 2.09
Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol (2010) 2.09
Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med (2014) 2.07
Immunology of psoriasis. Annu Rev Immunol (2014) 2.06
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol (2004) 2.05
DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A (2007) 2.04
The interaction of HIV with dendritic cells: outcomes and pathways. Trends Immunol (2007) 2.03
Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol (2006) 2.01